Skip to main content
Top
Published in: Clinical Research in Cardiology 9/2011

Open Access 01-09-2011 | Original Paper

Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction

Authors: Frank Edelmann, Raoul Stahrenberg, Götz Gelbrich, Kathleen Durstewitz, Christiane E. Angermann, Hans-Dirk Düngen, Thomas Scheffold, Christian Zugck, Bernhard Maisch, Vera Regitz-Zagrosek, Gerd Hasenfuß, Burkert M. Pieske, Rolf Wachter

Published in: Clinical Research in Cardiology | Issue 9/2011

Login to get access

Abstract

Background

Comorbidities negatively affect prognosis more strongly in heart failure with preserved (HFpEF) than with reduced (HFrEF) ejection fraction. Their comparative impact on physical impairment in HFpEF and HFrEF has not been evaluated so far.

Methods and results

The frequency of 12 comorbidities and their impact on NYHA class and SF-36 physical functioning score (SF-36 PF) were evaluated in 1,294 patients with HFpEF and 2,785 with HFrEF. HFpEF patients had lower NYHA class (2.0 ± 0.6 vs. 2.4 ± 0.6, p < 0.001) and higher SF-36 PF score (54.4 ± 28.3 vs. 54.4 ± 27.7, p < 0.001). All comorbidities were significantly (p < 0.05) more frequent in HFrEF, except hypertension and obesity, which were more frequent in HFpEF (p < 0.001). Adjusting for age and gender, COPD, anemia, hyperuricemia, atrial fibrillation, renal dysfunction, cerebrovascular disease and diabetes had a similar (p for interaction > 0.05) negative effect in both groups. Obesity, coronary artery disease and peripheral arterial occlusive disease exerted a significantly (p < 0.05) more adverse effect in HFpEF, while hypertension and hyperlipidemia were associated with fewer (p < 0.05) symptoms in HFrEF only. The total impact of comorbidities on NYHA (AUC for prediction of NYHA III/IV vs. I/II) and SF-36 PF (r 2) in multivariate analyses was approximately 1.5-fold higher in HFpEF, and also much stronger than the impact of a 10% decrease in ejection fraction in HFrEF or a 5 mm decrease in left ventricular end-diastolic diameter in HFpEF.

Conclusion

The impact of comorbidities on physical impairment is higher in HFpEF than in HFrEF. This should be considered in the differential diagnosis and in the treatment of patients with HFpEF.
Literature
1.
go back to reference Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al (2010) Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121(7):e46–e215PubMedCrossRef Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G et al (2010) Heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 121(7):e46–e215PubMedCrossRef
3.
go back to reference Krum H, Gilbert RE (2003) Demographics and concomitant disorders in heart failure. Lancet 362(9378):147–158PubMedCrossRef Krum H, Gilbert RE (2003) Demographics and concomitant disorders in heart failure. Lancet 362(9378):147–158PubMedCrossRef
4.
go back to reference Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42(7):1226–1233PubMedCrossRef Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R et al (2003) Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol 42(7):1226–1233PubMedCrossRef
5.
go back to reference Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT et al (2002) Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288(17):2144–2150PubMedCrossRef Kitzman DW, Little WC, Brubaker PH, Anderson RT, Hundley WG, Marburger CT et al (2002) Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 288(17):2144–2150PubMedCrossRef
6.
go back to reference Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259. doi:10.1056/NEJMoa052256 PubMedCrossRef Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM (2006) Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355(3):251–259. doi:10.​1056/​NEJMoa052256 PubMedCrossRef
7.
go back to reference Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ et al (2009) Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 119(24):3070–3077. doi:10.1161/CIRCULATIONAHA.108.815944 PubMedCrossRef Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ et al (2009) Relation of Disease Pathogenesis and Risk Factors to Heart Failure With Preserved or Reduced Ejection Fraction: Insights From the Framingham Heart Study of the National Heart, Lung, and Blood Institute. Circulation 119(24):3070–3077. doi:10.​1161/​CIRCULATIONAHA.​108.​815944 PubMedCrossRef
8.
go back to reference Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW et al (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group Trial. Circulation 114(5):397–403PubMedCrossRef Ahmed A, Rich MW, Fleg JL, Zile MR, Young JB, Kitzman DW et al (2006) Effects of digoxin on morbidity and mortality in diastolic heart failure: the Ancillary Digitalis Investigation Group Trial. Circulation 114(5):397–403PubMedCrossRef
9.
go back to reference Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777–781PubMedCrossRef Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ et al (2003) Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 362(9386):777–781PubMedCrossRef
10.
go back to reference Perez de Isla L, Canadas V, Contreras L, Almeria C, Rodrigo JL, Aubele AL et al (2009) Diastolic heart failure in the elderly: in-hospital and long-term outcome after the first episode. Int J Cardiol 134(2):265–270PubMedCrossRef Perez de Isla L, Canadas V, Contreras L, Almeria C, Rodrigo JL, Aubele AL et al (2009) Diastolic heart failure in the elderly: in-hospital and long-term outcome after the first episode. Int J Cardiol 134(2):265–270PubMedCrossRef
11.
go back to reference Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300(4):431–433PubMedCrossRef Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300(4):431–433PubMedCrossRef
12.
go back to reference Mehrhof F, Loffler M, Gelbrich G, Ozcelik C, Posch M, Hense HW, et al. (2009 Aug 11) A network against failing hearts-Introducing the German “Competence Network Heart Failure”. Int J Cardiol Mehrhof F, Loffler M, Gelbrich G, Ozcelik C, Posch M, Hense HW, et al. (2009 Aug 11) A network against failing hearts-Introducing the German “Competence Network Heart Failure”. Int J Cardiol
13.
go back to reference Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470PubMed Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 130(6):461–470PubMed
14.
go back to reference Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483PubMedCrossRef Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30(6):473–483PubMedCrossRef
15.
go back to reference Kinsella KaWH, U.S. Census Bureau. P95/09-1, An Aging World: 2008. International Population Reports. Washington, DC: U.S. Government Printing Office; 2009 Kinsella KaWH, U.S. Census Bureau. P95/09-1, An Aging World: 2008. International Population Reports. Washington, DC: U.S. Government Printing Office; 2009
16.
go back to reference Lakhan SE, Laird C (2009) Addressing the primary care physician shortage in an evolving medical workforce. Int Arch Med 2(1):14PubMedCrossRef Lakhan SE, Laird C (2009) Addressing the primary care physician shortage in an evolving medical workforce. Int Arch Med 2(1):14PubMedCrossRef
17.
go back to reference Primary Care Professionals: Recent Supply Trends, Projections, and Valuation of Services: United States Government Accountability Office (2008) Primary Care Professionals: Recent Supply Trends, Projections, and Valuation of Services: United States Government Accountability Office (2008)
18.
go back to reference Redelmeier DA, Tan SH, Booth GL (1998) The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 338(21):1516–1520PubMedCrossRef Redelmeier DA, Tan SH, Booth GL (1998) The treatment of unrelated disorders in patients with chronic medical diseases. N Engl J Med 338(21):1516–1520PubMedCrossRef
19.
go back to reference von Haehling S, Schefold JC, Hodoscek LM, Doehner W, Mannaa M, Anker SD et al (2010) Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. Clin Res Cardiol 99(2):107–113CrossRef von Haehling S, Schefold JC, Hodoscek LM, Doehner W, Mannaa M, Anker SD et al (2010) Anaemia is an independent predictor of death in patients hospitalized for acute heart failure. Clin Res Cardiol 99(2):107–113CrossRef
20.
go back to reference Luderitz B, Jung W (2000) Quality of life in patients with atrial fibrillation. Arch Intern Med 160(12):1749–1757PubMedCrossRef Luderitz B, Jung W (2000) Quality of life in patients with atrial fibrillation. Arch Intern Med 160(12):1749–1757PubMedCrossRef
21.
go back to reference Odden MC, Whooley MA, Shlipak MG (2004) Association of chronic kidney disease and anemia with physical capacity: the heart and soul study. J Am Soc Nephrol 15(11):2908–2915PubMedCrossRef Odden MC, Whooley MA, Shlipak MG (2004) Association of chronic kidney disease and anemia with physical capacity: the heart and soul study. J Am Soc Nephrol 15(11):2908–2915PubMedCrossRef
22.
go back to reference O’Donnell DE, Laveneziana P (2007) Dyspnea and activity limitation in COPD: mechanical factors. COPD 4(3):225–236PubMedCrossRef O’Donnell DE, Laveneziana P (2007) Dyspnea and activity limitation in COPD: mechanical factors. COPD 4(3):225–236PubMedCrossRef
23.
go back to reference Saraiva RM, Duarte DM, Duarte MP, Martins AF, Poltronieri AV, Ferreira ME et al (2005) Tissue Doppler imaging identifies asymptomatic normotensive diabetics with diastolic dysfunction and reduced exercise tolerance. Echocardiography 22(7):561–570PubMedCrossRef Saraiva RM, Duarte DM, Duarte MP, Martins AF, Poltronieri AV, Ferreira ME et al (2005) Tissue Doppler imaging identifies asymptomatic normotensive diabetics with diastolic dysfunction and reduced exercise tolerance. Echocardiography 22(7):561–570PubMedCrossRef
24.
go back to reference Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52(19):1527–1539PubMedCrossRef Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52(19):1527–1539PubMedCrossRef
25.
go back to reference Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C et al (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107(15):1991–1997PubMedCrossRef Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C et al (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107(15):1991–1997PubMedCrossRef
26.
go back to reference Guder G, Frantz S, Bauersachs J, Allolio B, Wanner C, Koller MT et al (2009) Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail 2(6):563–571PubMedCrossRef Guder G, Frantz S, Bauersachs J, Allolio B, Wanner C, Koller MT et al (2009) Reverse epidemiology in systolic and nonsystolic heart failure: cumulative prognostic benefit of classical cardiovascular risk factors. Circ Heart Fail 2(6):563–571PubMedCrossRef
27.
go back to reference Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR et al (2007) Cardiac structure and ventricular–vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115(15):1982–1990PubMedCrossRef Lam CS, Roger VL, Rodeheffer RJ, Bursi F, Borlaug BA, Ommen SR et al (2007) Cardiac structure and ventricular–vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 115(15):1982–1990PubMedCrossRef
28.
go back to reference Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108(1):7–13PubMed Levy D, Anderson KM, Savage DD, Kannel WB, Christiansen JC, Castelli WP (1988) Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108(1):7–13PubMed
29.
go back to reference Dwyer EM, Asif M, Ippolito T, Gillespie M (2000) Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. Am Heart J 139(2 Pt 1):297–304PubMedCrossRef Dwyer EM, Asif M, Ippolito T, Gillespie M (2000) Role of hypertension, diabetes, obesity, and race in the development of symptomatic myocardial dysfunction in a predominantly minority population with normal coronary arteries. Am Heart J 139(2 Pt 1):297–304PubMedCrossRef
30.
go back to reference Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC et al (2010) Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 96(7):528–532PubMedCrossRef Correa de Sa DD, Hodge DO, Slusser JP, Redfield MM, Simari RD, Burnett JC et al (2010) Progression of preclinical diastolic dysfunction to the development of symptoms. Heart 96(7):528–532PubMedCrossRef
31.
go back to reference Paulus WJ, van Ballegoij JJ (2010) Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol 55(6):526–537PubMedCrossRef Paulus WJ, van Ballegoij JJ (2010) Treatment of heart failure with normal ejection fraction: an inconvenient truth!. J Am Coll Cardiol 55(6):526–537PubMedCrossRef
32.
go back to reference Liao L, Jollis JG, Anstrom KJ, Whellan DJ, Kitzman DW, Aurigemma GP et al (2006) Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med 166(1):112–118PubMedCrossRef Liao L, Jollis JG, Anstrom KJ, Whellan DJ, Kitzman DW, Aurigemma GP et al (2006) Costs for heart failure with normal vs reduced ejection fraction. Arch Intern Med 166(1):112–118PubMedCrossRef
33.
go back to reference Alla F, Al-Hindi AY, Lee CR, Schwartz TA, Patterson JH, Adams KF Jr (2007) Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. Am Heart J 153(6):1074–1080PubMedCrossRef Alla F, Al-Hindi AY, Lee CR, Schwartz TA, Patterson JH, Adams KF Jr (2007) Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction. Am Heart J 153(6):1074–1080PubMedCrossRef
34.
go back to reference Kamp O, Metra M, De Keulenaer GW, Pieske B, Conraads V, Zamorano J et al (2010) Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clin Res Cardiol 99(2):75–82PubMedCrossRef Kamp O, Metra M, De Keulenaer GW, Pieske B, Conraads V, Zamorano J et al (2010) Effect of the long-term administration of nebivolol on clinical symptoms, exercise capacity and left ventricular function in patients with heart failure and preserved left ventricular ejection fraction: background, aims and design of the ELANDD study. Clin Res Cardiol 99(2):75–82PubMedCrossRef
35.
go back to reference Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT et al (2006) Systolic and diastolic heart failure in the community. JAMA 296(18):2209–2216PubMedCrossRef Bursi F, Weston SA, Redfield MM, Jacobsen SJ, Pakhomov S, Nkomo VT et al (2006) Systolic and diastolic heart failure in the community. JAMA 296(18):2209–2216PubMedCrossRef
Metadata
Title
Contribution of comorbidities to functional impairment is higher in heart failure with preserved than with reduced ejection fraction
Authors
Frank Edelmann
Raoul Stahrenberg
Götz Gelbrich
Kathleen Durstewitz
Christiane E. Angermann
Hans-Dirk Düngen
Thomas Scheffold
Christian Zugck
Bernhard Maisch
Vera Regitz-Zagrosek
Gerd Hasenfuß
Burkert M. Pieske
Rolf Wachter
Publication date
01-09-2011
Publisher
Springer-Verlag
Published in
Clinical Research in Cardiology / Issue 9/2011
Print ISSN: 1861-0684
Electronic ISSN: 1861-0692
DOI
https://doi.org/10.1007/s00392-011-0305-4

Other articles of this Issue 9/2011

Clinical Research in Cardiology 9/2011 Go to the issue